1Serrano M, Hannon GJ, Beach D. A new regulatory motif in cellcycle control causing specific inhibition of cyclin D/CDK4 [ J ].Nature, 1993,366(6 456) :704～707.
2Kamb A, Gruis NA, Weaver-Feldnaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types[ J ].Science, 1994,264(5 157) :436～440.
3Hunter T, Pines J. Cyclins and cancer. Ⅱ: Cyclin D and CDK inhibitors come of age[J]. Cell , 1994,79(4) :573～582.
4Grana X, Reddy EP. Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors ( CKIs ) [ J ].Oncogene, 1995,11(2) :211～219.
5Nishikawa R, Furnari FB, Lin H, et al. Loss of p16INK4 expression is frequent in high grade gliomas [ J ]. Cancer Res,1995,55(9) :1 941～1 945.
6Hayashi Y, Ueki K, Waha A, et al. Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme [ J ]. Brain Pathol, 1997, 7 (3): 871 ～875.
9Herman JG,Merlo A,Mao L, et al. Inactivation of the CAKN2/p16/MTS1 Gene is frequently associated with aberrant DNA methylation in all common human cancers[J ]. Cancer Research,1995,55(20) :4 525～4 530.
10Costello JF, Berger MS, Huang HS, et al. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation[ J ]. Cancer Res, 1996,56 (10): 2 405～2 410.
二级参考文献25
1Chang T G，Biochem Biophys Res Commun，1997年，230卷，1期，85页
8Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to P-73 at lp36, a region frequently deleted in neu- roblastoma and other human cancers. Cell, 1997, 90:809
9Chelly J, Montarras D, Pinset C, et al. Quantitative estimation of minor mRNAs by cDNA-polymerase chain reaction. Applica tion to dystrophin mRNA in cultured myogenic and brain cells.Europe J Biochemics, 1990, 187:691
10Jost C, Marin MC, Kaelin WG. 173 is a human P-73-related protein that can induce apoptosis. Nature, 1997, 389:191
4Fischer I,Gagner JP,Law M, et al. Angiogenesis in gliomas: biology and molecular Pathophysiology [J]. Brain Pathol, 2005,15(4) :297 - 310.
5Oshika Y, Nakamura M, Tokunaga T, et al. Ribozyme approach to downregulate vascular endothelial growth factor (VEGF) 189 expression in nonsmall cell lung cancer (NSCLC)[J]. European Journal of Cancer. 2000,36(18): 2390 - 2396.
6Sledge GW Jr. Vascular endothelial growth factor in breast cancer,biologic and the rapeutic aspects[J]. Sere in Oncol, 2002,29(3 suppl 11) :104- 110.
7G Graccone. EGFR inhibitors in the treatment of lung cancer [J]. EJC,2003,1(5) :$106.
8Hicklin DJ,Ellis LM. Role of the Vascular Endothelial Growth Factor PathWay in Growth and Angiogenesis[J]. Journal of Clinical Ontology,2005,23(5): 1011.
9Bachelder RE, Wendt MA, Mercurio Am. Vascular endothelial growth factor promotes carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4[J]. Cancer Res,2002,62(24) :7203.
10Sun FY,Guo X. Molecular and cellular mechanisms of neuroprotection by vascular endothelial growth factor[J]. J Neuro Sci Res, 2005,79 : 180 - 184.
